Expanded PET imaging time window adds flexibility for neuroendocrine tumor patients

January 20, 2021

Reston, Virginia--The imaging time window of 64Cu-DOTATATE positron emission tomography/computed tomography (PET/CT) for patients with neuroendocrine neoplasms can be expanded from one hour to three hours post-injection, according to new research published in the January issue of the Journal of Nuclear Medicine. In a head-to-head comparison of scans performed at the two time intervals, there were no significant differences in the number of lesions detected, and tumor-to-normal tissue ratios remained high in all key organs.

Previous research has demonstrated that 64Cu-DOTATATE PET imaging at one hour post-injection provides excellent lesion detection in patients with neuroendocrine neoplasms. "Given the long half-life and excellent image resolution of 64Cu-DOTATATE, we sought to investigate if the imaging time window for 64Cu-DOTATATE PET could be expanded from one hour to up to three hours without a loss in the ability to detect lesions," said Andreas Kjaer, MD, PhD, DMSc, professor at University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark, both in Copenhagen, Denmark.

In the prospective study, 35 patients with neuroendocrine neoplasms received 64Cu-DOTATATE whole-body PET imaging at both one hour post-injection and three hours post-injection. The number of lesions on the scans were counted and grouped according to organs or regions and were then compared. Uptake of 64Cu-DOTATATE in lesions and normal tissues was measured, and tumor-to-normal tissue ratios were calculated.

A total of 882 concordant lesions (visible on both the one-hour and three-hour post-injection 64Cu-DOTATATE PET) were found. Five discordant lesions, which were found on one of the PET scans but not the other, were noted; however, only four were considered true based on further imaging. Throughout the one to three hour post-injection imaging window, the tumor-to-normal tissue ratios were high in all key organs, including the liver, intestines, pancreas and bone.

"The high agreement in the number of lesions detected on both the one-hour and three-hour post-injection 64Cu-DOTATATE PET supports the rationale of expanding the imaging time window," stated Kjaer. "Since 64Cu-DOTATATE has a shelf-life of 24 hours, which is much longer than other PET imaging options, it offers greater convenience and flexibility for routine imaging of patients with neuroendocrine neoplasms. We expect to see more 64Cu-labeled PET tracers for routine use in the future."

Neuroendocrine neoplasms represent a heterogeneous class of diseases with large variability in aggressiveness and prognosis. These rare tumors most frequently originate from the pancreas, the gastrointestinal tract or the lung. Approximately 12,000 Americans are diagnosed with neuroendocrine neoplasms each year.
This study was made available online in May 2020 ahead of final publication in print in January 2021.

The authors of "64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours Post-Injection," include Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Helle H. Johannesen, Tina Binderup, Andreas Pfeifer, Jann Mortensen, Peter Oturai, Annika Loft, Anne K. Berthelsen and Andreas Kjaer, Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Denmark; Seppo W. Langer, Department of Oncology, Rigshospitalet, Copenhagen, Denmark, and Ulrich Knigge, Departments of Clinical Endocrinology and Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark. All departments are part of ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine and Molecular Imaging

Related Nuclear Medicine Articles from Brightsurf:

Nuclear medicine and COVID-19: New content from The Journal of Nuclear Medicine
In one of five new COVID-19-related articles and commentaries published in the June issue of The Journal of Nuclear Medicine, Johnese Spisso discusses how the UCLA Hospital System has dealt with the pandemic.

Story tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine
ORNL Story Tips: Shuffling atoms, thinning forests, fusion assembly and nuclear medicine.

Global nuclear medicine community shares COVID-19 strategies and experiences
In an effort to provide safer working environments for nuclear medicine professionals and their patients, clinics across five continents have shared their approaches to containing the spread of COVID-19 in a series of editorials, published ahead of print in The Journal of Nuclear Medicine.

Influence of the Journal of Nuclear Medicine jumps 25%
The Journal of Nuclear Medicine again ranks among the top 5 medical imaging journals in the world.

Nuclear medicine PSMA-targeted study offers new options for cancer theranostics worldwide
Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) describes a new class of radiopharmaceuticals, named radiohybrids (rh), that offer a fresh perspective on cancer imaging and radioligand therapy (theranostics).

Nuclear medicine imaging monitors effectiveness of therapy for melanoma patients
Nuclear medicine imaging with PET/CT can monitor the effectiveness of immunotherapy treatment for metastatic melanoma and predict outcome.

Prostate cancer radiotherapy more precisely targeted with nuclear medicine imaging
A nuclear medicine imaging procedure can pinpoint prostate cancer with superior accuracy, allowing more precisely targeted treatment, according to new research featured in the November 2018 issue of The Journal of Nuclear Medicine.

New nuclear medicine tracer will help study the aging brain
A new PET imaging radiotracer could help researchers understand neurodegenerative disease and the aging brain.

New nuclear medicine imaging method shows strong potential for cancer imaging
A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.

New nuclear medicine technique could help tackle brain disease
A new molecular imaging method can monitor the success of gene therapy in all areas of the brain, potentially allowing physicians to more effectively tackle brain conditions such as Parkinson's disease, Alzheimer's disease and multiple sclerosis.

Read More: Nuclear Medicine News and Nuclear Medicine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.